| Name | Title | Contact Details |
|---|
ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all stakeholders while keeping our research and development efforts focused on the needs of patients.
Trevena is a publicly traded clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. We have three programs in clinical development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently in phase 2 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in phase 1 testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
ReviveRX is a leading licensed mail-order pharmacy specializing in generic and compounded medications. Our compounds are expertly crafted in USP-certified clean rooms at our Houston headquarters, ensuring the highest quality standards. We work closely with best-in-class pharmacists, scientists, healthcare providers, and pharmaceutical manufacturers to provide high-quality, dependable products to our patients and clinic partners.
We are working to methodically engineer durable gene therapies for people with devastating diseases.